Go Pro
→ How to Think About a $500K Roth Conversion and the 35% Bracket (From SmartAsset) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Absci Corporation stock logo
ABSI
Absci
$8.82
+0.2%		$9.26
$2.24
▼
$12.06
$1.51B2.422.92 million shs2.13 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$150.37
-1.3%		$134.64
$77.58
▼
$156.92
$370.89B0.2111.02 million shs4.39 million shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$3.63
+5.5%		$3.33
$2.77
▼
$7.18
$1.94B1.0714.58 million shs29.01 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Absci Corporation stock logo
ABSI
Absci
0.00%+1.26%+6.27%+37.81%+270.59%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.00%+1.40%+17.23%+24.23%+78.57%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.00%+8.68%+14.15%+9.34%-21.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Absci Corporation stock logo
ABSI
Absci
$8.82
+0.2%		$9.26
$2.24
▼
$12.06
$1.51B2.422.92 million shs2.13 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$150.37
-1.3%		$134.64
$77.58
▼
$156.92
$370.89B0.2111.02 million shs4.39 million shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$3.63
+5.5%		$3.33
$2.77
▼
$7.18
$1.94B1.0714.58 million shs29.01 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Absci Corporation stock logo
ABSI
Absci
0.00%+1.26%+6.27%+37.81%+270.59%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.00%+1.40%+17.23%+24.23%+78.57%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.00%+8.68%+14.15%+9.34%-21.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Absci Corporation stock logo
ABSI
Absci
2.78
Moderate Buy$13.4352.25% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.65
Moderate Buy$148.60-1.18% Downside
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.20
Hold$8.06122.04% Upside

Current Analyst Ratings Breakdown

Latest ABSI, MRK, and RXRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/4/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$150.00 ➝ $170.00
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$155.00 ➝ $180.00
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$145.00 ➝ $170.00
8/21/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$140.00 ➝ $160.00
8/20/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$142.00 ➝ $170.00
8/20/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$145.00 ➝ $175.00
8/20/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$142.00 ➝ $150.00
8/20/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$116.00 ➝ $179.00
8/19/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/17/2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$5.30
(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Absci Corporation stock logo
ABSI
Absci
$1.56M969.66N/AN/A$1.43 per share6.17
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B5.71$11.43 per share13.16$17.02 per share8.83
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$74.68M26.02N/AN/A$1.71 per share2.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Absci Corporation stock logo
ABSI
Absci
-$115.18M-$0.80N/AN/AN/A-7,756.38%-61.71%-54.52%11/16/2026 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$1.25120.3015.576.544.77%16.73%6.13%10/29/2026 (Estimated)
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$644.76M-$1.04N/AN/AN/A-945.94%-50.41%-38.25%11/4/2026 (Estimated)

Latest ABSI, MRK, and RXRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Absci Corporation stock logo
ABSI
Absci
-$0.1910-$0.21-$0.0190-$0.21$0.92 million$0.32 million
8/5/2026Q2 2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.24-$0.25-$0.01-$0.25$10.97 million$7.67 million
8/4/2026Q2 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.26-$0.13+$0.13-$0.54$16.37 billion$16.61 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Absci Corporation stock logo
ABSI
Absci
N/AN/AN/AN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.26%+5.75%272.00%14 Years
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A

Latest ABSI, MRK, and RXRX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.61%9/15/20269/15/202610/7/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Absci Corporation stock logo
ABSI
Absci
N/A
10.63
10.63
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.22
1.32
1.10
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.01
5.03
5.03

Institutional Ownership

CompanyInstitutional Ownership
Absci Corporation stock logo
ABSI
Absci
52.05%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%

Insider Ownership

CompanyInsider Ownership
Absci Corporation stock logo
ABSI
Absci
10.52%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
6.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Absci Corporation stock logo
ABSI
Absci
210171.61 million153.56 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
400535.34 million499.74 millionOptionable

Recent News About These Companies

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.9% Higher - Here's What Happened
September 4 at 1:00 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-recursion-pharmaceuticals-nasdaq-rxrx-trading-69-higher-heres-what-happened-2026-09-04/
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?
September 4 at 12:37 PM  |  zacks.comhttps://www.zacks.com/stock/news/2985293/why-is-recursion-pharmaceuticals-rxrx-up-8-2-since-last-earnings-report?cid=cs-stocknewsapi-ft-realtime_blog-2985293
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
September 3 at 11:35 AM  |  zacks.comhttps://www.zacks.com/stock/news/2984455/can-rxrx-s-pipeline-expansion-strengthen-its-long-term-growth-outlook?cid=cs-stocknewsapi-ft-analyst_blog|quick_take-2984455
Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 30,000 Shares
September 3 at 6:37 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rxrx-insider-buying-and-selling-2026-09-03/
Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 30,000 Shares of Stock
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-recursion-pharmaceuticals-nasdaq-rxrx-director-blake-borgeson-sells-30000-shares-of-stock-2026-09-02/
Recursion Pharmaceuticals (NASDAQ:RXRX) Upgraded at Wall Street Zen
August 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30989292
Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Increased to Sell at Wall Street Zen
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-recursion-pharmaceuticals-nasdaq-rxrx-rating-increased-to-sell-at-wall-street-zen-2026-08-29/
Recursion Pharmaceuticals, Inc. (RXRX)
August 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/RXRX/earnings-calls/
Stock Traders Purchase High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-stock-traders-purchase-high-volume-of-recursion-pharmaceuticals-call-options-nasdaq-rxrx-2026-08-26/
Bank of America Corp DE Buys 384,486 Shares of Recursion Pharmaceuticals, Inc. $RXRX
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-buys-384486-shares-of-recursion-pharmaceuticals-inc-rxrx-2026-08-26/
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.3% - Here's What Happened
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-recursion-pharmaceuticals-nasdaq-rxrx-stock-price-up-63-heres-what-happened-2026-08-25/
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 7% - Here's What Happened
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-nasdaqrxrx-trading-down-7-heres-what-happened-2026-08-24/
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Average Rating of "Hold" by Analysts
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-inc-nasdaqrxrx-given-average-rating-of-hold-by-analysts-2026-08-24/
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 9.8% - Still a Buy?
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-nasdaqrxrx-shares-up-98-still-a-buy-2026-08-19/
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
August 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/zacks-analyst-blog-highlights-recursion-074300158.html
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says
August 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/contineum-disc-medicine-recursion-advance-150138340.html
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
August 17, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2975676/4-ai-powered-drug-discovery-stocks-to-watch-as-ai-reshapes-pharma?cid=cs-stocknewsapi-ft-analyst_blog|investment_ideas-2975676
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-highlights-ai-platform-roche-progress-and-pipeline-updates-2026-08-17/
Recursion (RXRX) Q2 2026 Earnings Call Transcript
August 12, 2026  |  fool.comhttps://www.fool.com/earnings/call-transcripts/2026/08/12/recursion-rxrx-q2-2026-earnings-call-transcript/
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934810-recursion-pharmaceuticals-inc-rxrx-presents-at-bank-of-america-smid-cap-virtual-conference
Stock Traders Purchase High Volume of Put Options on Recursion Pharmaceuticals (NASDAQ:RXRX)
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/stock-traders-purchase-high-volume-of-put-options-on-recursion-pharmaceuticals-nasdaqrxrx-2026-08-11/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Absci stock logo

Absci NASDAQ:ABSI

$8.82 +0.02 (+0.23%)
As of 09/4/2026 04:00 PM Eastern

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$150.37 -1.97 (-1.29%)
As of 09/4/2026 03:58 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$3.63 +0.19 (+5.52%)
As of 09/4/2026 04:00 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas